Life Sciences & Chemistry

Are you a founder in the field of life science and chemistry and on the lookout for financing? At HTGF, we not only offer you investment know-how, but also understand your specific needs and provide you with the right expertise to support your business ideas. We leverage our tailored network to help you achieve success.

Our Life Sciences & Chemistry team has the required start-up spirit! We have both entrepreneurial expertise and an understanding of science, medicine and practical applications. Having invested in over 200 life science and chemical companies since 2005, we know what really matters.

With our expertise and passion, we are at your side as a sparring partner from seed to exit – whether it be in the field of drug development and biotech, medtech and diagnostics, digital health, R&D tools or chemistry.

 Many steps must be taken to become a successful start-up

The right tools

We offer you the right tools to meet your individual challenges as a founder of a life sciences and chemical start-up:

Who we are

No results for this filter

Life Sciences & Chemistry Team

Dr. Angelika Vlachou

Partner

Dr. Bernd Goergen

Partner

Marco Winzer

Partner

Dr. Anke Caßing

Principal / Authorized Signatory

Dr. Caroline Fichtner

Principal / Authorized Signatory

Kay G. Balster

Principal / Authorized signatory

Dr. Frank Hensel

Principal / Authorized signatory

Dr. Martin Pfister

Principal / Authorized Signatory

Dr. Fabian Mohr

Senior Investment Manager

Dr. Nikolaus Raupp

Senior Investment Manager

Ulrike Kalapis

Investment Manager

Dr. Laura Pedroza

Investment Manager

Dr. Jan Engels

Investment Manager

Niels Sharman

Investment Manager

Dr. Katharina Severin

Investment Manager

Jakob Lilienweiss

Investment Analyst

Cedric Linke

Junior Analyst

What you can expect from us

• From the very early stage to the exit, we support you as partners with our know-how and understanding of your needs.
• We have an entrepreneurial spirit – many of us have founded our own companies and we have the necessary appetite for risk
• We understand how financing works and can call on our network
• We have backgrounds as scientists and know the pitfalls: manufacturing/CMC, regulatory affairs, market access, team growth, business development, etc.

The areas we invest in include:

Our Life Sciences & Chemistry Portfolio 

→ Life Sciences & Chemie Portfolio

Let’s turn ideas into reality!

Societal challenges, such as diseases or advancing climate change, require innovative solutions. And this is why pioneering start-ups in the fields of life sciences and healthcare, chemistry, food and agricultural technology, and new materials are playing a crucial role.

Germany has the platform to continue launching successful high-tech start-ups:

• Top-class research at universities and institutes
• Close cooperation between industry and consumers
• Transfer-enabling support

With your innovative start-up ideas, we can create sustainable and disruptive solutions together – what are we waiting for?

Looking to start a business? Contact our team here.

Is your pitch deck complete? Upload it here!

Topics that might interest you

Press

15. May 2023

Using an app to combat skin conditions: Nia Health receives millions in funding

The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including “Nia,” the most widely downloaded app for people with atopic dermatitis. The company has a network of renowned cooperation partners consisting of pharmaceutical companies, health insurance companies and clinics. The great potential lies above all in Nia Health’s ex

 

Press

19. April 2023

Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. The startup closes a 600,000 € pre-seed financing round with High-Tech Gründerfonds. The capital will be used to further develop Phialogics’ lead candidate in preclinical models in comparison to the current standard of care and other research approaches. This is a step forward to continue developing Phialogics’ i

 

Press

11. April 2023

Mosanna Therapeutics Announces a Seed Extension Financing Round to Complete Preparations to Enter the Clinic with MOS-118 in Metabolic Obstructive Sleep Apnea

Company pursuing a highly differentiated small molecule MOS-118 in Metabolic Obstructive Sleep Apnea. New investors, Supermoon Capital and HTGF, join founding investor Forty51 Ventures to complete the Seed syndicate. Company will use the funds to file an IND in preparation for a proof of mechanism and proof of concept in the clinic. Basel, Switzerland, April 11, 2023 – Mosanna Therapeutics AG, a Swiss Biotech company today announced that Supermoon Capital, a US based venture c

 

Press

23. March 2023

Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round

Munich, Germany, 23 March 2023 – mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors. mbiomics uses its proprietary, tailored high-resolution profiling platform and computat

 

Press

17. November 2022

ESy-Labs receives seed funding to advance its automated and AI-powered platform for sustainable electrosynthesis processes

Regensburg, November 17th 2022 –In a seed financing round, High-Tech Gründerfonds (HTGF) invests EUR 600,000 in ESy-Labs’ proprietary platform technology. The fresh capital raised will be used to expand the technical equipment and employ additional staff to further advance the ESy screening technology. Through the electrosynthesis of organic fine chemicals and electrolytic recycling processes it is possible to develop significantly more efficient and also new processes to make bett

 

Blog

18. May 2022

GWA Hygiene and Dräger: From collaboration to investment

How does a company specialized in medical and safety technology with a more than 130-year history end up getting together with a six-year-old start-up? Common goals, collaboration on an equal footing and good partners are key aspects in this regard. That is at least according to Jens Altmann, President Business Unit Data Business at Dräger, and Tobias Gebhardt, CEO at GWA Hygiene. Dräger, a global corporation, recently invested in High-Tech Gründerfonds (HTGF) portfolio company GWA Hygien